TO CONSULTING AGREEMENT. This Amendment No. 5 to Consulting Agreement (“Amendment No. 4”) is made as of February 1, 2021, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One Xxxxxxx Square, Building 1400 West, Suite 14303, Xxxxxxxxx, XX 00000 (“Company”) and Xxxxxxxx Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 00 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 (“Xxxxxxxx”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Xxxxxxxx and the Company dated as of March 13, 2013 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 (“Amendment”), dated as of November 4, 2002 and effective as of January 1, 2002 (the “Effective Date”) is entered into by and between Schrödinger, Inc. (“Schrödinger” or “Company”), a Delaware corporation with an address at 000 Xxxx 00xx Xxxxxx, 00xx Xxxxx, Xxx Xxxx, XX 00000, and Xxxxxxx X. Xxxxxxxx (“Consultant”), an individual with an address at [**].
TO CONSULTING AGREEMENT. Dear Rxxxxxx: This is in reference to the Consulting Agreement between VL42, d/b/a Omega Therapeutics, Inc., and Rxxxxxx X. Xxxxx, Ph.D. dated November 7, 2016 (the “Agreement”). All capitalized terms used in this letter and not otherwise defined in this letter shall have the same meaning as in the Agreement.
TO CONSULTING AGREEMENT. For W. Xxxxx Xxxx (Anticipated as of February 28, 2019) Grant Name Xxxxx Xxxxx Granted Vested Unvested Exercisable Exercised / Released Outstanding Restricted Shares Scheduled to Vest on 04/01/2019 02/26/2016 RS CIC- D&D $0.00 46,200 42,350 3,850 0 42,350 3,850 3,850 03/02/2017 RS CIC- D&D $0.00 36,135 21,077 15,058 0 21,077 15,058 3,011 03/02/2018 RS CIC D&D $0.00 22,585 5,646 16,939 0 5,646 16,939 1,882 03/02/2018 RS (Market Based) CIC-D&D $0.00 45,172 5,646 39,526 0 5,646 39,526 2,823 Total 150,092 74,719 75,373 0 74,719 75,373 11,566
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is entered into by and between AlloVir, Inc. (formerly ViraCyte, Inc.), a Delaware corporation (the “Company”), and Xxx Xxxx (“Consultant”), effective generally as of January 1, 2020 (the “Effective Date”).
TO CONSULTING AGREEMENT. THIS AMENDMENT No. 1 TO CONSULTING AGREEMENT (“Amendment No. 1”) is effective as of March 3, 2022 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at 400 Xxxxxxx Xxxxxx, Xxxx Xxxx, Xxxxxxxxxx 00000, and Fxxxx XxXxxxxxx (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made as of April 30, 2014 (“Effective Date”), by and between Dxxxxxxx Advisors, LLC (“Consultant”), a corporation located at 90 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 and Vedantra Pharmaceuticals, Inc., a Delaware corporation (“Company”), located at One Kxxxxxx Square, Building 1000 Xxxx, Xxxxx 00000, Xxxxxxxxx, XX 00000. Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Dxxxxxxx Advisors, LLC and the Company dated as of March 13, 2014 (“Agreement”).
TO CONSULTING AGREEMENT. Please acknowledge your acceptance of the foregoing Amendment by signing and returning a copy to the undersigned whereupon it shall become a binding agreement between us. PERFORMANCE HEALTH TECHNOLOGIES, INC. By: Name: Title: XXXXXX XXXXX SECURITIES, INC. By: Name: Title:
TO CONSULTING AGREEMENT. This Addendum No. 1 to Consulting Agreement (“First Consulting Agreement Addendum”), effective as of October 17, 2011, is incorporated by reference in, appended to and made a part of the Consulting Agreement, dated June 13, 2011 (“Consulting Agreement”), executed by Metro Bank (“Metro”) and Xxxxx X. Xxxxxxxx, Xx.(“Consultant”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“First Modification”), executed this 8th day of February, 2012, is made by and between Xxxxx X. Xxxxxxxx, Xx. (“Xxxxxxxx”), with an address of 00 Xxxxxxx Xxxxx, Xxxxxxx, Xxx Xxxxxx 00000, and Metro Bancorp, Inc. and Metro Bank (collectively, “Metro”), each with an office located at 0000 Xxxxxx Xxxxxx, Harrisburg, PA 17111.
